Urine protein marker of ovarian cancer and diagnosis application thereof

Abstract

The invention relates to a urine protein marker of ovarian cancer and a diagnosis application thereof, in particular to a urine protein marker obtained by using in-situ injection of ovarian cancer cells in a rat ovary and mass spectrum analysis, and application in the diagnosis and disease course monitoring of human ovarian cancer. The urine protein marker is selected from cystathionine-gamma-lyase, a Rab GDP dissociation inhibitor beta, an ester hydrolase C11orf54 homolog, neutral and alkaline amino acid translocator rBAT, apolipoprotein A-1, OX-2 membrane glycoprotein, charged multivesicularbody protein 5, beta-amino hexosaminidase subunit beta, monocyte differentiation antigen CD14, glyceraldehydes-3-phosphate dehydrogenase, cadherin 1, gastricsin, a serine protease inhibitor A3M, alpha-1-asialoglycoprotein and the like. Differential protein obtained from the marker provides a simpler, quicker and non-invasive choice for early diagnosis and disease course monitoring of ovarian cancer.

Description

technical field [0001] The invention relates to clinical medicine; in particular, it relates to a urine protein marker related to human ovarian cancer. Specifically, the present invention relates to urine protein markers related to the diagnosis and / or monitoring of human ovarian cancer obtained by using an orthotopic rat disease model of epithelial ovarian cancer and proteomics technology of mass spectrometry and its use. Background technique [0002] Disease biomarkers are measurable changes associated with pathophysiological processes, which are used to diagnose diseases, monitor disease course, predict disease prognosis, and evaluate treatment effects, etc. [0003] Urine, as the liquid excretion excreted by the body through the urinary system and urinary tract, is not regulated by the homeostasis mechanism, and can enrich the changes in the whole body, and is early and sensitive. Urine is an ideal source of disease markers. Because of its early and sensitive changes, i...

AI Technical Summary

Problems solved by technology

For a long time, although blood ovarian cancer markers, abdominal ultrasound and vaginal ultrasound have been plagued by low sensitivity and specificity, and treatment methods such as surgery, radiotherapy, chemotherapy, and biological targeted therapy have improved, but 5 The annual survival rate is only about 40%, and the prognosis is poor [4]

Despite the continuous development of diagnostic techniques for ovarian cancer in recent years, there are still many patients who cannot be diagnosed in the early stages of ovarian cancer with existing diagnostic techniques

Images